Drug intelligence / Profile preview

bicalutamide + fluciclovine F 18

Development stage: Unknown
Lead developer: Blue Earth Diagnostics
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Oral, Intravenous

Overview

This is a combination of bicalutamide, a nonsteroidal anti-androgen medication used for treating prostate cancer, and fluciclovine F 18, a radiopharmaceutical used for positron emission tomography (PET) imaging to detect recurrent prostate cancer. Bicalutamide blocks androgen receptors to inhibit the growth of prostate cancer cells, while fluciclovine F 18 helps in diagnostic imaging to detect prostate cancer recurrence.

Brand names: Posluma
Other names: flotufolastat F 18

Targets

SLC1A5 (Alanine/serine/cysteine transporter 2)AR (Adrenergic receptors)

Beyond the preview

Go deeper on bicalutamide + fluciclovine F 18.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bicalutamide + fluciclovine F 18.

Explore the full profile